Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C2C_ASC66
- Development stage
- Unknown
- Lead developer
- Cell to Cure
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
C2C_ASC66 is a standardized, high-diversity live biotherapeutic product (LBP) developed by the Danish biotechnology company Cell to Cure. It is specifically designed to treat Autism Spectrum Disorder (ASD) and comorbid gastrointestinal (GI) disorders by leveraging the gut-brain axis. The product consists of a complex consortium of commensal bacteria derived from healthy donor stool, processed to ensure safety and high microbial diversity. The therapeutic rationale is based on the observation that individuals with ASD often exhibit gut dysbiosis and increased intestinal permeability. By restoring a balanced microbial ecosystem, C2C_ASC66 aims to reduce the production of neurotoxic metabolites and systemic inflammation, thereby improving both GI function and core autistic behaviors. It is typically administered as part of a Microbiota Transfer Therapy (MTT) protocol, which involves a pre-treatment phase of antibiotics and bowel cleansing to facilitate donor microbe engraftment.
Beyond the preview
Go deeper on C2C_ASC66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C2C_ASC66.